<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02022371</url>
  </required_header>
  <id_info>
    <org_study_id>13/0244</org_study_id>
    <nct_id>NCT02022371</nct_id>
  </id_info>
  <brief_title>Prostate Cancer Genomic Heterogeneity</brief_title>
  <acronym>PROGENY</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>University College London Hospitals</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University College London Hospitals</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to carry out very detailed genetic testing on prostate cancer
      cells. The reason to do this is because researchers do not fully understand

        -  How prostate cancer develops

        -  Why some cancer cells spread and others do not

        -  Why some cancer cells respond to treatment and others do not

      Researchers and doctors know that 1 in 3 of the male population over the age of 50 has cancer
      cells in their prostate. However, most of these men will never know they have it and it will
      not affect their quality of life or their life expectancy. However, some cancers can be
      aggressive. These are more likely to spread outside of the prostate and cause problems.
      Doctors do not have an accurate way to tell the difference between aggressive cancer and
      those which will not cause any problems. Even within one prostate some tumours are aggressive
      and others do not cause a problem during the lifetime of a patient. In fact, even within one
      tumour, different cells may behave differently. In other words, one part of the tumour may be
      aggressive and spread, whilst another part of the same tumour does not. This project will try
      to find out more about what makes different tumours and different parts of the same tumour
      aggressive or harmless.

      It is important to find out what makes some cancer cells spread and others stay where they
      are. For the investigators to do this they need to collect fresh samples of cancer tissue
      from the prostate and from different areas of a tumour within the prostate. This is because
      biopsies used to diagnose or exclude cancer by the hospital laboratory are not good enough to
      give investigators detailed genetic information. These biopsies have been put into a chemical
      called formalin which reduces the quality of the genetic information.

      Investigators are therefore asking patients who are undergoing prostate biopsies as part of
      their normal care to allow them to take additional biopsies for the purpose of this study.
      This may be the first time patients are having biopsies. Or, patients may be having biopsies
      after treatment that has been given for the cancer and the doctors are concerned the
      treatment is not working.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cancer is a genetic disease, caused by mutations in genes that lead to increased cell
      proliferation and survival. Importantly, the genetic changes vary dramatically between
      individual prostate cancer patients and the specific combination of mutations within a
      patient's cancer is thought to determine tumour aggressiveness and clinical outcome.

      Personalized medicine approaches aim to decipher the genetic code of a patient's tumour in
      order to identify cancers which will behave aggressively and need treatment. However,
      extensive intra-tumour heterogeneity (ITH) has been discovered in several solid tumour types,
      complicating the identification of the relevant genetic changes as they may not be present
      throughout the entire tumour and are likely to be missed by tumour biopsies. ITH is thus a
      major hurdle for the implementation of personalized cancer treatment approaches.

      Investigators have developed genetic technologies that allow them to measure ITH in solid
      tumours and they now want to apply these to patients with prostate cancer to define the
      extent and the clinical importance of ITH in this disease which is currently unknown. This
      will involve looking at the control of genes in the cancer cells which make some tumours more
      aggressive than others. This may help in predicting which tumours are important and need to
      be targeted and those that could be left so that too much tissue damage does not occur as a
      result of therapy. Finding out why some cancer cells spread and others do not may also help
      to identify novel molecular targets that could be used to prevent the development of
      metastases.

      Patients with suspected prostate cancer usually have scans and then prostate biopsies. These
      biopsies are needed by the pathologist to make a proper diagnosis and cannot be used for full
      genetic analysis. So, investigators will ask patients whether they would be willing to give
      some extra samples of tissue while undergoing these routine biopsies.

      Defining ITH in prostate cancer will provide important insights into the genetics of prostate
      cancer development and metastatic progression and is a key prerequisite for the development
      of reliable personalized cancer medicine approaches. Thus this study will significantly
      advance researchers' efforts to predict which tumours are dangerous and in need of urgent
      treatment and those that could safely be left untreated which would spare these patients the
      unnecessary side effects. Investigators think that this research work will have a major
      impact on the use of next generation sequencing in the management of prostate cancer through
      an in-depth understanding of how common are differences between and within individual cancer
      lesions. Investigators also want to find out whether these differences, if they exist, are
      important in tumour development and spread to other areas. Investigators think that the
      characterization of these differences will allow them to successfully use this information to
      group patients undergoing treatment using molecular 'signatures' so that treatment is
      targeted rather than applied in a 'sledge-hammer' approach. Investigators believe that
      without studies like PROGENY, doctors will instead rely on data from single tumour biopsies
      which can be misleading since single biopsies may not have sampled the most aggressive tumour
      area. Finally, investigators think that PROGENY will reveal how prostate cancers evolve over
      time and which of these changes lead to metastases and ultimately kill the patient. These are
      called phylogenetic studies and will help work out the main (or 'trunk') genomic changes from
      later events in 'branches'. This may allow researchers to focus their drug discovery efforts
      on the common 'trunk' genomic changes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2014</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumour heterogeneity</measure>
    <time_frame>At time of biopsy</time_frame>
    <description>To define the extent of inter/intra-tumour heterogeneity and its association with disease stage at diagnosis and Gleason grade by deep genomic sequencing of multiple regions of intermediate Gleason grade tumours and high Gleason grade tumours, with and without metastatic disease.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clonal origin of secondary tumours</measure>
    <time_frame>At time of biopsy</time_frame>
    <description>Through clonal re-ordering and multi-regional prostate mapping, determine whether satellite tumour nodules in high grade prostate cancers represent monoclonal disease related to the index lesion or the evolution of polyclonal cancers by evaluating the deep genomic signatures of primary and secondary lesions within the prostate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Relationship of tumours to metastases</measure>
    <time_frame>At time of biopsy</time_frame>
    <description>Identify genotype requirements for metastasis development by deep sequencing DNA from the associated metastases from the same patient to reconstruct clonal evolution from primary tumour to metastatic sites and identify evolutionary bottlenecks governing metastasis development that may be targetable for clinical benefit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Identifying genomic signature of tumour DNA in blood</measure>
    <time_frame>At time of biopsy</time_frame>
    <description>To determine whether ultra-deep sequencing of circulating plasma DNA can reconstruct inter/intra-tumour heterogeneity and clonal evolution occurring in men who have failed first- and second-line therapies (for localized and metastatic disease).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genomic signature changes in tumour DNA in blood when drug resistance develops</measure>
    <time_frame>At time of biopsy</time_frame>
    <description>To determine whether ultra-deep sequencing of circulating plasma DNA can reconstruct inter/intra-tumour heterogeneity and clonal evolution occurring during the acquisition of castration resistant disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship of tumour genomics with imaging</measure>
    <time_frame>At time of biopsy</time_frame>
    <description>To determine the association of inter/intra-tumour heterogeneity with functional imaging with multi-parametric magnetic resonance imaging</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>PROSTATE CANCER</condition>
  <arm_group>
    <arm_group_label>Targeted biopsy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Snap frozen targeted biopsies of the prostate for genomic analysis</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Targeted biopsies of the prostate</intervention_name>
    <description>Multiple biopsies from a MRI lesion for analysis of intratumour heterogeneity</description>
    <arm_group_label>Targeted biopsy</arm_group_label>
    <other_name>SmartTarget Biopsies of the prostate for snap frozen tissue in order to obtain genetic heterogeneity</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Treatment na√Øve group

               1. Men with no prior diagnosis of prostate cancer undergoing prostate biopsy based
                  on identified lesions on imaging

               2. Men with a raised PSA above 15ng/ml

               3. Men giving informed consent

        Treated men

          1. Men undergoing tissue biopsy for suspicion of prostate cancer recurrence following
             previous local or systemic therapy based on identified lesions in multi-parametric
             MRI, bone-scan, choline PET/CT, or PET/MRI

             Exclusion Criteria:

               -  1. Unable to have MRI scan or CT scan, or in whom artefact would reduce scan
                  quality

          2. Unable to have prostate biopsy

          3. Unable to undergo biopsy for metastatic evaluation

          4. On immunosuppression or predefined immunosuppressed state

          5. A coagulopathy predisposing to bleeding

          6. Unable to give informed consent
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University College London Hospitals</name>
      <address>
        <city>London</city>
        <zip>NW1 2BU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 15, 2013</study_first_submitted>
  <study_first_submitted_qc>December 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 27, 2013</study_first_posted>
  <last_update_submitted>May 8, 2017</last_update_submitted>
  <last_update_submitted_qc>May 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University College London Hospitals</investigator_affiliation>
    <investigator_full_name>Hashim Uddin Ahmed</investigator_full_name>
    <investigator_title>MRC Clinician Scientist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

